ONKURE THERAPEUTICS, INC. (OKUR) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -62.14M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 46.95M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-62.14M | (m) | (m) | $46.95M | (m) | (m) |
| 2026-03-31 | $-61.56M | (m) | (m) | $46.95M | (m) | (m) |
| 2025-12-31 | $-62.95M | (m) | (m) | $48.26M | (m) | (m) |
| 2025-09-30 | $-67.52M | (m) | (m) | $51.90M | (m) | (m) |
| 2025-06-30 | $-63.53M | (m) | (m) | $50.10M | (m) | (m) |
| 2025-03-31 | $-61.55M | (m) | (m) | $48.24M | (m) | (m) |
| 2024-12-31 | $-54.39M | $0.00 | (m) | $43.80M | (m) | (m) |
| 2024-09-30 | $-45.60M | (m) | (m) | $24.04M | (m) | (m) |
| 2024-06-30 | $-61.82M | (m) | (m) | $36.76M | (m) | (m) |
| 2024-03-31 | $-76.49M | (m) | (m) | $50.56M | (m) | (m) |
| 2023-12-31 | $-83.05M | (m) | (m) | $56.61M | (m) | (m) |
| 2023-09-30 | $-72.61M | (m) | (m) | $49.37M | (m) | (m) |
| 2023-06-30 | $-65.56M | (m) | (m) | $45.68M | (m) | (m) |
| 2023-03-31 | $-56.96M | (m) | (m) | $39.42M | (m) | (m) |
| 2022-12-31 | $-53.85M | (m) | (m) | $37.70M | (m) | (m) |
| 2022-09-30 | $-49.91M | (m) | (m) | $34.45M | (m) | (m) |
| 2022-06-30 | $-48.82M | (m) | (m) | $33.83M | (m) | (m) |
| 2022-03-31 | $-45.62M | (m) | (m) | $31.98M | (m) | (m) |
| 2021-12-31 | $-39.82M | (m) | (m) | $28.17M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-19.55M | (m) | (m) | $15.94M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |